L (T+O 2.5/5 µg) and 0.140 L (T+O 5/5 µg). SGRQ total scores improved by 5.1 (O 5 µg), 5.7 (T 2.5 µg), 5.6 (T 5 µg), 6.2 (T+O 2.5/5 µg) and 6.8 points (T+O 5/5 µg); differences between T+O 5/5 µg and O 5 µg and T 5 µg were statistically significant (p

Conclusions T+O 5/5 µg significantly improved lung function and provided symptomatic benefit over O 5 µg and T 5 µg.

P255 ONCE-DAILY TIOTROPIUM RESPIMAT® ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA

¹DMG Halpin, ²P Paggiaro, ³E Bleecker, ⁴M Engel, ⁴P Moroni-Zentgraf, ⁴H Schmidt, ⁵HAM Kerstjens. ¹Royal Devon and Exeter Hospital, Exeter, UK; ²University of Pisa, Pisa, Italy; ³Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, USA; ⁴Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riss, Germany; ⁵University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

10.1136/thoraxjnl-2014-206260.383

Background A reduction in asthma exacerbation risk may provide improvements in clinical burden, patient experience and healthcare costs. In Phase III trials, once-daily tiotropium (delivered via the Respimat® SoftMist™ inhaler) added on to at least inhaled corticosteroids (ICS) improved lung function in patients with symptomatic asthma. We investigated exacerbation risk in each trial.

Methods Five Phase III, double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Patients received tiotropium Respimat® 5 µg or placebo as add-on to at least ICS maintenance therapy (Table). Pre-planned co-primary or secondary end points were time to first severe exacerbation and time to any asthma worsening.

Results Mean baseline% of predicted forced expiratory volume in 1 second, seven-question Asthma Control Questionnaire score and ICS dose (µg) were: 56.0 ± 13.1, 2.6 ± 0.7, 1198 ± 539 (PrimoTinA-asthma®); 75.1 ± 11.5, 2.2 ± 0.5, 660 ± 213 (MezzoTinA-asthma®); 77.7 ± 11.9, 2.1 ± 0.4, 381 ± 78 (GraziaTinA-asthma®). Tiotropium Respimat® 5 µg reduced severe asthma exacerbation risk by at least 21% in all three severity cohorts (Table) and asthma worsening risk versus placebo in all trials, with a statistically significant reduction in the PrimoTinA-asthma® trial.

Abstract P255 Table 1

		Severe asthma exacerbations, proportion of patients (%)			
	Background	Tiotropium		HR ^a	
Trial	medication	Respimat ® 5 µg	Placebo	(95% CI)	p value
	ICS + LABA				
PrimoTinA- asthma ^{®b}	(>800 µg budesonide or equivalent)	122/453 (26.9)	149/454 (32.8)	0.79 (0.62, 1.00)	0.034
	ICS (400–800 µg				
MezzoTinA- asthma ^{®c}	budesonide or equivalent)	31/513 (6.0)	43/518 (8.3)	0.72 (0.45, 1.14)	0.164
	ICS (200–400 µg				
GraziaTinA- asthma ^{®d}	budesonide or equivalent)	1/151 (0.7)	4/151 (2.6)	0.25 (0.03, 2.24)	0.216

^aHazard ratio; time to first severe exacerbation (versus placebo, <1 favours tiotropium Respimat®); ^bBaseline to Week 48; ^cBaseline to Week 24; ^dBaseline to time of last event

Conclusion Once-daily tiotropium Respimat® 5 µg add-on to at least ICS maintenance therapy consistently reduced exacerbations across asthma severities and so may be a beneficial add-on option to reduce current and future exacerbation risk.

P256 SAFETY OF ONCE-DAILY TIOTROPIUM AND OLODATEROL FIXED-DOSE COMBINATION VIA THE RESPIMAT IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN TWO 1-YEAR STUDIES

¹R Buhl, ²R Abrahams, ³L Bjermer, ⁴E Derom, ⁵M Fležar, ⁶J Hébert, ⁷A Veale, ⁸L Grönke, ⁹A Hamilton, ⁸K Tetzlaff, ¹⁰L Korducki, ¹¹H Huisman, ¹¹S Waitere-Wijker, ¹²L McGarvey. ¹Pulmonary Department, Mainz University Hospital, Mainz, Germany; ²Morgantown Pulmonary Associates, Morgantown, West Virginia, USA; ³Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden; ⁴Ghent University Hospital, Ghent, Belgium; ⁵Klinika Golnik, Golnik, Slovenia; ⁶Centre de Recherche Appliquée en Allergie de Québec (CRAAQ), Québec, Canada; ⁷Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, Australia; ⁸Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany; ⁹Boehringer Ingelheim, Burlington, Ontario, Canada; ¹⁰Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA; ¹¹Boehringer Ingelheim B. V., Alkmaar, The Netherlands; ¹²Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK

10.1136/thoraxjnl-2014-206260.384

Introduction The fixed-dose combination (FDC) of tiotropium (T), a once-daily long-acting muscarinic antagonist, and olodaterol (O), a once-daily long-acting β₂-agonist, is currently being evaluated in chronic obstructive pulmonary disease (COPD).

Two 52-week, Phase III replicate pivotal studies were conducted to assess the efficacy and safety of FDCs of T and O (T+O) delivered via Respimat® Soft Mist™ inhaler in patients (pts) with GOLD Stage 2–4 COPD. Pooled safety data from the two studies are presented here.

Methods These were double-blind, randomised, parallel-group studies with 5 arms: O 5 µg, T 2.5 µg, T 5 µg, T+O 2.5/5 µg, T+O 5/5 µg. Key inclusion criteria were: age ≥40 years, diagnosis of COPD, smoking history >10 pack-years. Pts with a history of asthma or significant disease other than COPD were excluded. Adverse events (AEs) were reported throughout the studies.

Results A total of 5162 pts were randomised and treated. In general, AEs, serious AEs and fatal AEs were balanced across treatment groups. In particular, frequencies of AEs in the cardiac disorders System Organ Class (SOC) and respiratory disorders SOC were similar.

Abstract P256 Table 1

	Pts with AE, %				
	O 5 µg n = 1038	T 2.5 µg n = 1032	T 5 µg n = 1033	T+O 2.5/5 µg n = 1030	T+O 5/5 µg n = 1029
Total AEs	76.6	73.4	73.3	74.7	74.0
Serious AEs	17.4	15.1	16.7	16.3	16.4
Fatal AEs	1.3	1.2	1.6	1.4	1.7
Cardiac disorders*	5.7	5.8	5.3	5.8	4.5
Respiratory, thoracic and mediastinal disorders*	45.3	43.9	42.7	38.2	39.4

*MedDRA SOC

Conclusions T+O FDCs were safe and well tolerated. In comparison to the individual components, there was no notable increase in AEs with T+O FDCs.

P257 SUB-OPTIMAL INHALER TECHNIQUE IN PATIENTS AGED OVER 75 YEARS

¹S Vandermolen, ²J Berner, ¹M Almond, ¹F Huwez. ¹Southend University Hospital, Essex, UK; ²Barts and the London Medical School, London, UK

10.1136/thoraxjnl-2014-206260.385

Introduction and objectives NICE guidelines highlight the importance of adequate inhaler technique to ensure sufficient drug delivery in asthma and C. O. P. D. Whilst adequate inhaler technique can be a problem for patients of any age, the delivery of inhaled medication continues to be a particular problem for elderly patients. Despite the existence of pressurised metered-dose inhalers and breath-actuated inhalers, physical and cognitive impairment continues to make the use of hand-held inhalers difficult in the elderly. It is therefore likely that inhaler use in the elderly is suboptimal, regardless of device used.

Methods We assessed 50 consecutive patients aged over 75 years with C. O. P. D or asthma at our centre (mean age 78.24 ± 7.32). All had inhaler therapy prescribed prior to examination. Two observers assessed inhaler technique against guidelines adapted from the National Asthma Council of Australia¹ (see Table). Patients used either an Evohaler (pressurised metered-dose inhaler) or Accuhaler (breath-actuated inhaler) according to their choice.

Results In the Evohaler group (25 patients), the average age was 78 (±5.5) with an average score of 6.6 (±1.81) / 10. In the Accuhaler group (25 patients), average age was 77 (±6.4) with an average score of 7.2 (±2.0) / 10. 'Crucial' steps to adequate inhaler technique were also assessed.² The score in the Evohaler group was 4.4 (±1.2) / 6, and in the Accuhaler group was 4.3 (±1.0) / 6.

Conclusion This study shows that despite the availability of both Evohaler (pressurised metered-dose inhaler) and Accuhaler (breath-actuated inhaler) effective use by the elderly is still sub-optimal. The very elderly need extra support when considering and prescribing inhalers. Whilst many centres have 'good inhaler technique' as a pillar of their COPD care bundle, it may be the case that specialist services, including the use of specialist devices, directed at the elderly may help to alleviate the problems of physical and cognitive impairment when using inhalers.

Abstract P257 Table 1

Step	EVOHALER	ACCUHALER
1	Remove cap	Open using thumb grip
2	Hold inhaler upright and shake	Load dose by sliding lever until it clicks
3	Breathe out	Breathe out
4	Put mouthpiece between lips, close lips to form seal	Put mouthpiece between lips, close lips to form seal
5	Breathe in and press down	Breathe in steadily
6	Continue to breathe in	Continue to breathe in
7	Hold breath 10 secs	Hold breath 10 secs
8	Remove inhaler	Remove inhaler
9	Breathe out	Breathe out
10	Replace cap	Close cover

REFERENCES

- 1 National Asthma Council Australia. Inhaler technique in adults with asthma or COPD. Melbourne: National Asthma Council Australia, 2008
- 2 Newman S. P. Inhaler treatment options in COPD. *Eur Respir Rev* 2005;14 (96):102-108

P258 THE 24-HOUR LUNG FUNCTION PROFILE OF ONCE-DAILY TIOTROPIUM AND OLODATEROL FIXED-DOSE COMBINATION COMPARED WITH PLACEBO AND MONOTHERAPIES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

¹E Derom, ²J Westerman, ³L Grönke, ⁴A Hamilton, ⁵C Li, ⁶KM Beeh. ¹Ghent University Hospital, Ghent, Belgium; ²Pulmonary and Sleep Associates of Jasper, Jasper, Alabama, USA; ³Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany; ⁴Boehringer Ingelheim, Burlington, Ontario, Canada; ⁵Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA; ⁶Insaf GmbH Institut Für Atemwegsforschung, Wiesbaden, Germany

10.1136/thoraxjnl-2014-206260.386

Introduction Tiotropium (T), a once-daily long-acting muscarinic antagonist, is a well-established first-line maintenance treatment in chronic obstructive pulmonary disease (COPD). Olodaterol (O) is a once-daily long-acting β_2 -agonist, recently approved in several EU countries. This study investigated the 24-hour bronchodilator profile of once-daily fixed-dose combinations (FDCs) of T and O delivered via the Respimat® Soft Mist™ inhaler in patients with Global initiative for chronic Obstructive Lung Disease 2–4 COPD.

Methods This double-blind, placebo-controlled, Phase III, incomplete crossover study randomised 219 patients to receive four of the following treatments for 6 weeks (with a 3-week washout period in between): placebo, O 5 μ g, T 2.5 μ g, T 5 μ g, T+O FDC 2.5/5 μ g, T+O FDC 5/5 μ g. The primary end point was forced expiratory volume in 1 second (FEV₁) area under the curve from 0–24 h (AUC_{0–24}) after 6 weeks. Secondary end points included additional spirometric parameters over 24 h and body plethysmography parameters in a sub-set of patients (2:30 and 22:30 h post-dose).

Results The 24-hour time profiles for both FDCs were similar, with clear, consistent increases in FEV₁ compared to placebo and monotherapies. For FEV₁ AUC_{0–24}, both FDCs were significantly superior to placebo (T+O 5/5 μ g: 0.280 L, p < 0.0001; T+O 2.5/5 μ g: 0.277 L, p < 0.0001) and monotherapies (T+O 5/5 μ g: 0.110–0.127 L, p < 0.0001; T+O 2.5/5 μ g: 0.107–0.124 L, p < 0.0001). There were significantly greater increases in trough FEV₁ with both FDCs compared to placebo (0.201–0.207 L, p < 0.0001) and monotherapies (T+O 5/5 μ g: 0.079–0.107 L, p < 0.0001; T+O 2.5/5 μ g: 0.073–0.101 L, p < 0.0001). In the body plethysmography sub-study, both FDC doses separated from

Abstract P258 Figure 1 Adjusted mean Fev₁ over 24 h post dose after 6 weeks of treatment (full analysis set)